Hematopoietic stem-cell transplantation in the pediatric population

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
Assess comparative benefits and harms of hematopoietic stem-cell transplantation (HSCT) versus standard therapies or disease natural history in pediatric (age .21 years) patients with malignant solid tumors, inherited metabolic diseases, or autoimmune diseases.

Authors' conclusions
Evidence demonstrating benefit or harm of HSCT versus standard therapies or disease natural history was insufficient for most pediatric indications.

Final publication URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Infant, Newborn; Adolescent; Child; Child, Preschool; Hematopoietic Stem Cell Transplantations

Language Published
English

Country of organisation
United States

English summary
An English language summary is available.

Address for correspondence
AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov

AccessionNumber
32013000182

Date abstract record published
20/03/2013